Latest News and Press Releases

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing a deep and diverse pipeline of adeno-associated virus (AAV)-based gene...

– In the initial clinical data from low-dose cohort of the ongoing trial, we observed that LX1001 expressed the protective APOE2 protein in the CNS and decreased core Alzheimer’s disease-related...

- Phase 1/2 clinical trial expected to initiate in mid-2022 - - LX2006 is the first clinical-stage program from LEXEO’s cardiovascular pipeline and the third clinical-stage gene therapy candidate...

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic...

NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic...

Financing led by D1 Capital Partners and Eventide Asset Management with participation from additional investors including returning Series A investors Proceeds to support continued preclinical...

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, today announced...

LEXEO obtains exclusive rights to three investigational AAV-mediated gene therapy programs for rare cardiac disorders, all of which have no existing disease-modifying treatments available Strategic...

NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a clinical-stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric...

Data evaluating intravenous delivery of the AAVrh.10 viral vector show effectiveness in providing high levels of gene transfer to the heart for the potential treatment of rare cardiac diseases ...